Dr Bence Jones and the history of free light chains

From Wikilite

Share/Save/Bookmark
Jump to: navigation, search
Chapter

2

SECTION 1 - Introduction

Dr Bence Jones and the history of free light chains

Contents

Summary:

Timeline of the history of free light chains

Henry Bence Jones
Figure 2.1. Henry Bence Jones. (A) Albumen print by Maull c.1850s (B) Charcoal and chalk on paper by Richmond 1865 (reproduced with permission from The Royal Institution, London and The Bridgeman Art Library).


Although immunoglobulin FLCs are synonymous with Bence Jones proteins, history might have been more generous to others involved in their discovery [1][2][3][4][5].

On Friday, October 30th 1845, the 53 year old Dr William MacIntyre, physician to the Western General Dispensary, St. Marylebone, London, left his rooms in Harley Street. He had been called to see Mr Thomas Alexander McBean, a 45 year-old, highly respectable grocer, who had severe bone pain and fractures. He had been under the care of his general practitioner, Dr Thomas Watson, for several months. Upon examination of the patient, William MacIntyre noted the presence of oedema. Considering the possibility of nephrosis, he tested the urine for albumin. To his consternation, the albuminous protein precipitate found on warming the urine, uncharacteristically, redissolved when heated to 75°C.

Both Dr MacIntyre and Dr Watson then sent urine samples to the chemical pathologist at St.George's Hospital. A note accompanying the urine sent by Dr Watson read as follows:-

"Dear Dr Bence Jones, The tube contains urine of very high specific gravity. When boiled it becomes highly opaque. On the addition of nitric acid, it effervesces, assumes a reddish hue, and becomes quite clear; but as it cools assumes the consistence and appearance which you see. Heat reliquifies it. What is it?"

Over the next two months, the patient deteriorated, became emaciated, weak, and was racked with pain. He eventually died on January 1st 1846, in full possession of his mental faculties. Dr MacIntyre subsequently published the post-mortem examination and the description of the peculiar urine in 1850 [6]. Unfortunately for him, Henry Bence Jones [7][8] (Figure 2.1) had already described the patient’s urinary findings in two, single author articles, one of which was published in The Lancet, in 1847. He considered the protein to be an “hydrated deutoxide of albumen”. He wisely commented:

“I need hardly remark on the importance of seeking for this oxide of albumen in other cases of mollities ossium”.

Bence Jones’s reputation was assured, while the contributions of his colleagues were consigned to the footnotes of history.

For all the apparent injustice to his colleague,William MacIntyre, Henry Bence Jones achieved much else in his career. He published over 40 papers and became rich and famous based on his clinical practice, lecturing and original observations and was elected to fellowship of The Royal Society at the tender age of 33. Florence Nightingale once described him as “the best chemical doctor in London.” Surprisingly, there was no mention of Bence Jones protein in his obituary and the eponym (and the hyphen in his name) was not used until after his death [2].

By 1909, over 40 cases of Bence Jones proteinuria had been reported [9], and the protein was thought to originate in bone marrow plasma cells that were first identified by Waldeyer in 1875. In 1922, Bayne-Jones and Wilson characterised two types of Bence Jones protein by observing precipitation reactions using antisera made by immunising rabbits with the urine of several patients. The proteins were classified as group I and group II types. However, it was not until 1956 that Korngold and Lapiri, using the Ouchterlony technique, showed that antisera raised against the different groups also reacted with myeloma proteins. As a tribute to their observations the two types of Bence Jones protein were designated kappa and lambda (κ and λ). Edelman and Gally, in 1962, subsequently showed that FLCs prepared from IgG monoclonal proteins were the same as Bence Jones protein. It had taken 117 years from the original observation for the function of Bence Jones protein to be finally determined. Remarkably, the format of the urine test had remained unchanged for a similar period. The following is a protocol from Levinson and MacFate's “Clinical Laboratory Diagnosis”, a standard textbook published in 1946.

Bence-JonesProtein Test
Principle. Bence-Jones protein is soluble in urine at room and body temperature. When the urine is heated to 40°C, a white cloud appears and at 60°C, a distinct precipitate forms. The precipitate disappears on boiling but reappears on cooling. Excessive amounts of acid or salt will prevent the appearance of the precipitate.
Reagent. Acetic Acid, approximately 10% aqueous solution.
Procedure. Add urine to a 6-inch test tube until it is about two-thirds full. Place in a water bath and heat slowly. Do not allow the bottom of the test tube to touch the bottom of the beaker, as it may become hotter than the rest of the water. Suspend a thermometer in the water bath. Note the temperature and the appearance of the urine every few minutes, especially between the temperatures of 40°C - 60°C. If a slight cloud appears when the urine is heated to the boiling point, 100°C, add a few drops of acetic acid. This will dissolve any phosphates that have separated out. If a precipitate forms at the boiling point, it is due to albumin. Boil the urine with a few drops of dilute acetic acid, filter rapidly, and repeat the test on the cooled filtrate.
Interpretation. Bence-Jones protein is found in urine in many cases of multiple myeloma, osteogenic sarcoma, osteomalacia, carcinomatosis.
(The hyphen was only added after his death)

In parallel with the clinical and scientific observations of the role of Bence Jones protein, electrophoretic techniques for protein separation were entering clinical laboratories. Longsworth et al., in 1939, recognised tall, narrow-based, “church spire” peaks in the sera of patients with MM, using moving boundary protein electrophoresis. Electrophoresis was subsequently improved by using paper as a substrate followed by cellulose acetate then agarose in the 1950's and 1960's. Finally, immunofixation electrophoresis became established in the 1980's [10].

Clear identification of κ and λ molecules was possible with the use of antibodies specific for each type of protein. Immunodiffusion was initially used [11], followed by immunoelectrophoresis in 1953 [12], radial immunodiffusion and ultimately nephelometry and turbidimetry. However, serum assays for Bence Jones protein (serum free light chains - sFLCs) remained unattainable because the antibodies could not distinguish between sFLCs and the overwhelming amounts of light chains bound in intact immunoglobulin molecules.

The first successful attempt to measure FLCs in serum was in 1975. Size-separation column chromatography [13][14][15], was used to isolate them from intact immunoglobulins, prior to analysis. Although the results were accurate and showed the potential use of serum analyses, these assays were clearly impractical for routine use.

Subsequent assays focussed on the use of antibodies directed against “hidden” epitopes on FLC molecules. These are located at the interface between the light and heavy chains of intact immunoglobulins and become detectable when the FLCs are unbound. Radioimmunoassays and enzyme immunoassays using polyclonal antisera against FLCs were used to analyse urine samples but specificity remained inadequate for serum measurements [16][17] and variations in FLC polymerisation caused measurement errors [18][19].

The use of monoclonal antibodies was an obvious approach to improving specificity but satisfactory reagents were difficult to develop [20][21][22][23] and their use was restricted to radio-immunoassays and enzyme immunoassays. Attempts were made to develop turbidimetric [24][25] and latex-enhanced nephelometric assays [26], using polyclonal antibodies but they could not detect normal sFLC concentrations, and cross-reactions with intact immunoglobulins were unacceptable. In 2001, immunoassays, based on polyclonal antibodies, were finally developed that could measure FLCs at normal serum concentrations [27]. Their utility was quickly made apparent when monoclonal FLCs were detected in the sera of most patients classified as having “nonsecretory myeloma” [28]. Furthermore, as described in The Lancet, all of 224 patients with LCMM who had Bence Jones proteinuria, also had elevated sFLC concentrations [29]. The serum tests were also better at detecting residual disease than urinalysis. Further studies have shown that sFLC assays can be used for screening symptomatic patients (Chapter 23) , are more sensitive than urine tests (Chapter 24) and are markers for progression in MGUS (Chapter 19).

These results and many others, herald the widespread use of sFLC immunoassays. The enduring story of Bence Jones protein and Bence Jones proteinuria may be entering its final chapter, 160 years after it began.

Test Questions
  1. Who was the first person to observe “Bence Jones proteinuria?”
  2. What is the origin of the names, kappa and lambda?


Chapter 1 Back to Contents Page Chapter 3

References

  1. Clamp JR. Some aspects of the first recorded case of multiple myeloma. Lancet 1967; 2: 1354 – 6 PMID: : 4170040
  2. 2.0 2.1 Rosenfeld L. Henry Bence Jones (1813-1873): the best "chemical doctor" in London. Clin Chem 1987; 33: 1687 – 92 PMID: 3304718
  3. Kyle RA. Multiple myeloma: an odyssey of discovery. Br J Haematol 2000; 111: 1035 – 44 PMID: 11167737
  4. Kyle RA. Henry Bence Jones - physician, chemist, scientist and biographer: a man for all seasons. Br J Haematol 2001; 115: 13 – 8 PMID: 11722404
  5. Hajdu SI. A note from history: the first biochemical test for detection of cancer. Ann Clin Lab Sci 2006; 36: 222 – 3 PMID: 16682523
  6. MacIntyre W. Case of mollities and fragilitas ossium, accompanied with urine strongly charged with animal matter. Med Chir Tran 1850; 33: 211 – 232
  7. Jones HB. Papers on Chemical Pathology, Lecture III. Lancet 1847; II: 88-92.
  8. Jones HB. On the new substance occurring in the urine of a patient with mollities ossium. Philosophical Transactions of the Royal Society of London. Series B: Biological Sciences 1848;138: 55-62.
  9. Parkes Weber F, Ledingham JCG. A note on the histology of a case of Myelomatosis (Multiple Myeloma) with Bence-Jones protein in the urine (Myelopathic Albumosuria). Proc R Soc Med 1909; 2 (Pathol Sect): 193 – 206
  10. Whicher JT, Hawkins L, Higginson J. Clinical applications of immunofixation: a more sensitive technique for the detection of Bence Jones protein. J Clin Pathol 1980; 33: 779 – 80 PMID: 7000839
  11. Ouchterlony O. Antigen-antibody reactions in gels. IV. Types of reactions in coordinated systems of diffusion. Acta Pathol Microbiol Scand 1953; 32: 230 – 40 PMID: 13079779
  12. Grabar P, Williams CA. [Method permitting the combined study of the electrophoretic and the immunochemical properties of protein mixtures; application to blood serum.]. Biochim Biophys Acta 1953; 10: 193 – 4 PMID: 13041735
  13. Sölling K. Free light chains of immunoglobulins in normal serum and urine determined by radioimmunoassay. Scand J Clin Lab Invest 1975; 35: 407 – 12 PMID: 810881
  14. Sölling K. Polymeric forms of free light chains in serum from normal individuals and from patients with renal diseases. Scand J Clin Lab Invest 1976; 36: 447 – 52 PMID: 824709
  15. Cole PW, Durie BG, Salmon SE. Immunoquantitation of free light chain immunoglobulins: applications in multiple myeloma. J Immunol Methods 1978; 19: 341 – 9 PMID: 416145
  16. Robinson EL, Gowland E, Ward ID, Scarffe JH. Radioimmunoassay of free light chains of immunoglobulins in urine. Clin Chem 1982; 28: 2254 – 8 PMID: 6812991
  17. Brouwer J, Otting-van de Ruit M, Busking-van der Lely H. Estimation of free light chains of immunoglobulins by enzyme immunoassay. Clin Chim Acta 1985; 150: 267 – 74 PMID: 3933858
  18. Sölling K. Free light chains of immunoglobulins. Scand J Clin Lab Invest Suppl 1981; 157: 1 – 83 PMID: 6797039
  19. Heino J, Rajamaki A, Irjala K. Turbidimetric measurement of Bence-Jones proteins using antibodies against free light chains of immunoglobulins. An artifact caused by different polymeric forms of light chains. Scand J Clin Lab Invest 1984; 44: 173 – 6 PMID: 6426036
  20. Ling NR, Lowe J, Hardie D, Evans S, Jefferis R. Detection of free kappa chains in human serum and urine using pairs of monoclonal antibodies reacting with C kappa epitopes not available on whole immunoglobulins. Clin Exp Immunol 1983; 52: 234 – 40 PMID: 6190595
  21. Axiak SM, Krishnamoorthy L, Guinan J, Raison RL. Quantitation of free kappa light chains in serum and urine using a monoclonal antibody based inhibition enzyme-linked immunoassay. J Immunol Methods 1987; 99: 141 – 7 PMID: 3106501
  22. Nelson M, Brown RD, Gibson J, Joshua DE. Measurement of free kappa and lambda chains in serum and the significance of their ratio in patients with multiple myeloma. Br J Haematol 1992; 81: 223 – 30 PMID: 1643019
  23. Abe M, Goto T, Kosaka M, Wolfenbarger D, Weiss DT, Solomon A. Differences in kappa to lambda (kappa:lambda) ratios of serum and urinary free light chains. Clin Exp Immunol 1998; 111: 457 – 62 PMID: 9486419
  24. Hemmingsen L, Skaarup P. The 24-hour excretion of plasma proteins in the urine of apparently healthy subjects. Scand J Clin Lab Invest 1975; 35: 347 – 53 PMID: 810880
  25. Tillyer CR, Iqbal J, Raymond J, Gore M, McIlwain TJ. Immunoturbidimetric assay for estimating free light chains of immunoglobulins in urine and serum. J Clin Pathol 1991; 44: 466 – 71 PMID: 1906071
  26. Wakasugi K, Suzuki H, Imai A, Konishi S, Kishioka H. Immunoglobulin free light chain assay using latex agglutination. Int J Clin Lab Res 1995;25: 211 – 5 PMID: 8788550
  27. Bradwell AR, Carr-Smith HD, Mead GP, Tang LX, Showell PJ, Drayson MT, Drew R. Highly sensitive, automated immunoassay for immunoglobulin free light chains in serum and urine. Clin Chem 2001; 47: 673 – 80 PMID: 11274017
  28. Drayson M, Tang LX, Drew R, Mead GP, Carr-Smith H, Bradwell AR. Serum free light-chain measurements for identifying and monitoring patients with nonsecretory multiple myeloma. Blood 2001; 97: 2900 – 2 Chem 2001; 47: 673 – 80 PMID: 11313287
  29. Bradwell AR, Carr-Smith HD, Mead GP, Harvey TC, Drayson MT. Serum test for assessment of patients with Bence Jones myeloma. Lancet 2003; 361: 489 – 91 Chem 2001; 47: 673 – 80 PMID: 12583950

Wikilite.com is an online educational resource provided by The Binding Site Group Ltd and is intended for our UK customers. To read our disclaimer and full terms and conditions, please visit Chapter 35.

Personal tools